Temporal N -glycoproteomic differences between COVID-19 survivors and non-survivors at hospital admission and beyond

Clicks: 23
ID: 329594
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #31 of 69 articles by views in glycobiology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
COVID-19 has proven to have a wide range of symptoms in human patients, prompting investigation into relevant biomarkers and underlying biological mechanisms. In this study, we aimed to develop a robust quantitative N-glycoproteomics approach for complex plasma samples and to characterize the altered glycosylation profiles associated with COVID-19 severity. We analyzed plasma samples from 16 survivors and 15 non-survivors, collected at three distinct time points following hospital admission. Using data-dependent acquisition (DDA) mass spectrometry, combined with a spectral library and the "match-between-runs" strategy, we profiled 397 unique glycopeptides and 62 glycan species, derived from 50 proteins across 86 glycosylation sites. By assessing both cross-sectional differences and longitudinal changes, we identified several site-specific glycosylation alterations that may serve as potential markers of disease severity. The most notable site-specific change was in the complement C1q A-chain (C1QA) at Asn146, with non-survivors having less fucosylation at hospital admission. We also observed increased bisection of immunoglobulins in non-survivors (IgG3/4 Asn177 and IgM Asn146) and glycosylation pattern changes in acute-phase proteins. Longitudinally, the fucosylation levels of C1QA increased in the non-survivors, whereas they decreased in the survivors. These findings highlight the potential value of site-specific glycoproteomic profiling for improving the molecular understanding of COVID-19 severity.
Reference Key
openalex_W7214120409 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xue Yu, Kelly Dingess, Rita Pavasini, Gianluca Calogero Campo, Spadaro Savino, Albert J R Heck, Karli R. Reiding
Journal glycobiology
Year 2026
DOI
10.1093/glycob/cwag079
URL
https://doi.org/10.1093/glycob/cwag079
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.